{"description":"Only unexpected adverse events, grades III-IV acute GVHD, and chronic GVHD were collected.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":2,"description":"Without LSC, standard cytarabine consolidation\n\nCytarabine consolidation: Cytarabine-based consolidation per institutional standards.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"title":"No Leukemia Stem Cells - Consolidation"},{"deathsNumAffected":0,"deathsNumAtRisk":2,"description":"LSC present, randomized to cytarabine consolidation\n\nCytarabine consolidation: Cytarabine-based consolidation per institutional standards.","id":"EG001","otherNumAffected":0,"otherNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"title":"Leukemia Stem Cells - Consolidation"},{"deathsNumAffected":1,"deathsNumAtRisk":6,"description":"LSC present, randomized to allogeneic transplant\n\nAllogeneic transplant: Allogeneic stem cell transplant per institutional standards.","id":"EG002","otherNumAffected":0,"otherNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"title":"Leukemia Stem Cells - Transplant"}],"frequencyThreshold":"0","timeFrame":"Collected monthly for up to 3.5 years."}